Merck agrees to buy privately held Peloton Therapeutics for $1 billion in cash, giving it access to Peloton's molecular therapy treatments for patients with cancer and other non-oncology diseases.
Shares of Pfizer rise Thursday after the drugmaker is named a 'top pick' at Credit Suisse following a meeting the analysts had with Pfizer's management team.
J&J reveals its plans to boost growth within its Janssen pharmaceutical business over the next five years.
Shares of ImmunoGen plunge after the U.S. Food and Drug Administration requests additional trials to 'evaluate the safety and efficacy' of one of its cancer-fighting treatments.
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
Drugmaker Catalent reaches an agreement to buy closely held Paragon Bioservices, the latest deal in the burgeoning gene-therapy treatment space.
Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.
Shares of Zogenix plunge after the FDA rejects an initial marketing application for one of its more promising epilepsy treatment drugs.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.